Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population for its steroid-eluting sinus implants.
California device maker Intersect ENT (NSDQ:XENT) announced this week that it enrolled the 1st patient in its PROGRESS clinical trial, evaluating the company's Propel Mini sinus implant for treatment of frontal sinusitis.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.
Technology titan Apple provides its new mobile HealthKit data-aggregation app to researchers at Standford and Duke Universities.
MASSDEVICE ON CALL — Apple (NSDQ:AAPL) is driving home its growing partnership with the healthcare industry by lending its new HealthKit iPhone application to researchers at Stanford and Duke Universities.
Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
RBC is also the exclusive provider of AdvantageRF - a portfolio of flexible mix and match solution tools for RF product developers that reduce risks, enhance reliability and sustainability, as well as accelerate time to market and lower R & D costs.